

MEDICAL DIRECTIVE

Family Health Team

Taddle Creek

Title:	Pelvic Examination	Number:	TCFHT-MD06		
Activation Date:	01-09-2011	Review Date:	Apr 24, 2024		
Next Review due:	Apr 24, 2025				
Sponsoring/Contact	Alissia Valentinis, MD				
Person(s)	790 Bay, Suite 522, Toron	to, Ontario			
(name, position, contact particulars):	416-591-1222				
	Vicki McGregor RN 790 Bay St, Suites 300 & 3 416-960-1366	02			
Order and/or Delegat	ed Procedure:	Appendix Attached: <u>X</u> No _ Title:	_ Yes		
Pelvic Examination cor	sists of the following:				
 Inspection of exter 	nal genitalia				
 Speculum evaluation 	on of the vagina and cervix				
 Specimen Collectio 	n – Papanicolaou test, cervio	, 0			
Recipient Patients:		Appendix Attached: <u>No X</u> Title: Appendix A – Authorizer			
the Authorizer AppBe a person with a	L of a TCFHT primary care prov proval Form (Appendix A) cervix who requires routine as identified in this directive	ider who has approved th			
Authorized Implemen	iters:	Appendix Attached: No _X Title: Appendix B – Implement			
Implementers must be (under the supervision	TCFHT employed Regulated of a physician).	Health Care Providers, RI	N or Physician Assistant		
Implementers must co (Appendix B):	mplete the following prepar	ation and sign the Implem	enter Approval Form		

• Assess own knowledge, skill, and judgment to competently perform pelvic examinations (Note: this requires implementers to have the applicable added skills to perform the controlled act of placing an instrument, hand, or finger beyond the labia majora).

Practical requirements

- Successfully complete the McMaster University's Clinical Skills in Gynecological Health Workshop
- After completing the theoretical preparation below, demonstrate ability to competently perform pelvic examination and pap test under supervision of an authorizing primary care provider on 3 occasions

Theoretical requirements

- Review Ontario Cervical Screening Cytology Guidelines (Cancer Care Ontario, June 2020), accessed from: <u>https://www.cancercareontario.ca/en/guidelines-advice/cancer-</u> continuum/screening/resources-healthcare-providers/cervical-screening-guidelines-summary
- Review female pelvic anatomy and physiology and physical examination & health assessment in an advanced health assessment text (ex. Jarvis or equivalent reference).
- Review "The gynecologic history and pelvic examination" article (Carusi, 2024) retrieved from Uptodate: <u>http://www.uptodate.com/contents/the-gynecologic-history-and-pelvic-examination?source=search_result&search=bimanual+exam&selectedTitle=1%7E150</u>
- Review the Alberta Health Service's Cervical Cancer Screening Learning Module for RNs and other resources available at: <u>https://screeningforlife.ca/for-health-providers/cervical-screening-information/?d=2#rn_pap_module_resources</u>
- Review the Cancer Care Manitoba's Cervical Cancer Screening Module for Health Care Providers <u>https://www.cancercare.mb.ca/screening/hcp/education</u>
- View the "Pelvic examination" video at <u>Toronto Video Atlas of Surgery (TVASurg)</u>
- Review Hologic Thinprep pap test collection instructions here: <u>https://youtu.be/w_kZNiF8akg</u>
- View the video, "At your Cervix: What's normal anyway?" <u>https://youtu.be/COL76Img-NM</u>
- Review the Labia Library for anatomical variations <u>http://www.labialibrary.org.au/photo-gallery/</u>
- Review specimen collection instructions for paps, endocervical and vaginal swabs, accessible from Gamma Dynacare <u>https://www.dynacare.ca/specialpages/secondarynav/find-a-</u> <u>test/nat/pap%C2%A0smear.aspx?sr=ont&st=pap&</u> as well as Hologic Aptima swab instructions at <u>https://youtu.be/DLvsgQ217Mc?feature=shared</u>
- Review Public Health Ontario Specimen Collection guidelines for collecting gonorrhoeae, chlamydia, trichomonas NAAT and vaginal culture specimens, accessible from: https://www.publichealthontario.ca/en/Laboratory-Services/Test-Information-Index
- Review the Public Health Ontario bacterial STI testing quick reference guide at: <u>https://www.publichealthontario.ca/en/diseases-and-conditions/infectious-diseases/sexually-transmitted-infections</u>
- Review Toronto Public Health Sexual Health Information for Health Professionals, including STI treatment guidelines, accessible from: <u>https://www.toronto.ca/community-people/health-wellness-care/information-for-healthcare-professionals/sexual-health-info-for-health-professionals/</u>
- Review the Ontario Canadian Guidelines on Sexually Transmitted Infections (PHAC, 2016), accessible from http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php
- Review the cervical cancer screening section and "Tips for providing paps to trans men" in the Rainbow Health Ontario's Long-term Preventive Care recommendations for trans masculine patients: https://www.rainbowhealthontario.ca/TransHealthGuide/gp-mascht.html#sec5

Last Updated Feb 15, 2023 by Vicki McGregor RN

- Review RNAO's Woman Abuse: Screening, identification and initial response accessible from https://rnao.ca/bpg/guidelines/woman-abuse-screening-identification-and-initial-response
- Be familiar with your professional practice standards that protect patients from abuse by a health professional, including the College of Nurses of Ontario's Code of Conduct and Therapeutic Nurse-Client Relationship
- Review CMPA's guidance on respecting professional boundaries during intimate procedures or exams: <u>https://www.cmpa-acpm.ca/en/education-events/good-practices/professionalism-</u>ethics-and-wellness/boundaries
- •

Indications:	Appendix Attached: <u>X</u> No Yes Title:

• Patients with a cervix aged 21-years and older who are, or have ever been, sexually active presenting for routine cervical cancer screening as per the most recent Ontario Cervical Screening Cytology guidelines. Follow Cancer Care Ontario's most recent Cervical Screening Cytology Guidelines for age of initiation.

• Contraindications:

- Paediatric, pregnant patients, or patients with personal history of complex medical issues should be seen by their primary care provider
- In 2016, the Canadian Taskforce on Preventive Health Care adopted the 2014 American College of Physicians' recommendation **against** performing a pelvic examination to screen for non-cervical cancer, pelvic inflammatory disease, or other gynecological conditions in asymptomatic women.

Considerations

- Patient informed of purposes, risks, harms, and benefits of testing, including when results will be available, and potential follow up required if test is positive or negative.
- Patient is informed of mandatory reporting to public health and the importance of contact notification in the event of positive STI results.
- Patient able to give informed consent and is cooperative and does not need restraint.
- Implementers understand the prevalence of abuse and the triggering nature of this exam. Implementers will accommodate patient requests, communicate and stop the exam if requested by the patient.

Consent:	Appendix Attached: <u>X</u> No <u>Yes</u> Title:					
• Patient's consent is implied for implementer to perform examination, if patient has presented to clinic seeking testing, and is a Family Health Team patient, where inter-professional practic is expected. Further verbal consent will be obtained prior to pelvic exam.						
• Providers discuss with the patient the option bringing their own chaperone. This may contr	of having a chaperone during the exam, including ribute to both patient and provider comfort.					
Guidelines for Implementing the	Appendix Attached: No _X _ Yes					
Order/Procedure:	Title: Appendix C – Sample Lab Requisition					
	Appendix D – Sample Cytology Requisition					
For eligible and appropriate patients, the implementer:						
• Determine patient eligibility for cervical cancer screening according to the Ontario Cervical						

Screening Program guidelines and patient history.

- Obtains detailed history (presenting symptoms, date and results of last pap and HPV test, HPV vaccination, history of STIs or abnormal pap tests, sexual history, date of last menstrual period, contraception, vaginal symptoms, and routine screening for abuse)
- Provides patient education of what testing will be done, review equipment, what to expect, and allow time for questions.
- Informs patient of purposes, risks, harms, and benefits of testing, including when results will be available, and potential follow up required if test is positive or negative.
- Advises patient to empty bladder prior to pelvic examination for their comfort.
- Allows patient to undress in private, providing clean clinical garment, allowing patient to wear their own clothes as much as possible for their comfort.
- Prepares lab requisitions for cytology using the supervising primary care provider initials in Practice Solutions. If patient reports vaginal symptoms of infection (e.g., atypical vaginal discharge, foul odour, itching), intermenstrual spotting, post-coital spotting, and/or the patient is, or has been, sexually active with risk factors for STIs, prepare requisitions for STI tests and/or vaginal C&S (see Appendices C and D).
- Lab Requisitions should be signed as below:
 - o Signature of implementer
 - o Print Implementer Name/Primary Care Provider Name (Medical Directive TCFHT-MD06)
- Gathers and labels equipment required (ex. gloves, speculum, lubricant, appropriate swabs, liquid based cytology container, cytology broom)
- According to clinical practice guidelines, and maintaining infection control practices:
 - o Assesses external genitalia
 - Assesses internal genitalia using speculum of appropriate size and shape
 - o Performs specimen collection
- Informs patient of physical assessment findings, noting any abnormal findings, potential diagnoses, and follow up. If there are abnormal findings during exam, implementer will review with primary care provider and arrange for follow up with the PCP, as necessary.
- Patient is informed of mandatory reporting and the importance of contact notification in the event of positive STI results implementer to update contact information in EMR if required.
- Implementer to follow up with lab results promptly and review these findings with the patient's primary care provider in a timely manner so that appropriate treatment or follow-up care is implemented. Implementer will ensure that this is communicated to the patient.

Documentation and Communication:	Appendix Attached: <u>X</u> No <u>Y</u> es Title:
----------------------------------	--

- Documentation in the patient's EMR needs to include: name and number of the directive, name of the implementer (including credential), and name of the physician/nurse practitioner authorizer responsible for the directive and patient.
- Information regarding implementation of the procedure and the patient's response should be documented in the patient's EMR, in accordance with standard documentation practice (College of Nurses of Ontario, 2008).
- Standard documentation is recommended for prescriptions, requisitions, and requests for consultation.
- Implementer will send a message in Practice Solutions to patient's primary care provider, notifying him/her that patient was seen, and to review note in EMR for details.

Review and Quality Monitoring Guidelines:	Appendix Attached: <u>X</u> No Yes Title:
 Routine review will occur annually on the an a collaboration between the authorizing prin implementers. 	niversary of the activation date. Review will involv nary care providers and the authorized
 clinical practice guidelines, and particularly if unexpected outcomes, the directive will be r pracititioner and a mimimum of one implem use of this directive are identified, TCFHT mu undertake a review of the directive by the au authorized implementers. This medical directive can be placed on hold 	eviewed by the authorizing physician/nurse enter. At any such time that issues related to the ust act upon the concerns and immediately uthorizing primary care providers and the if routine review processes are not completed, or old, implementers cannot perform the procedures
References:	
	:://screeningforlife.ca/wp-content/uploads/ACCSP
RN-Guideline pdf	
Cancer Care Manitoba's Cervical Cancer Screeni	ng Module for Health Care Providers
Cancer Care Manitoba's Cervical Cancer Screenin https://www.cancercare.mb.ca/screening/hcp/e Cancer Care Ontario (2020). Screening Guidelines	ng Module for Health Care Providers I <mark>ducation</mark> s – Cervical Cancer. Retrieved from
Cancer Care Manitoba's Cervical Cancer Screenin https://www.cancercare.mb.ca/screening/hcp/e Cancer Care Ontario (2020). <i>Screening Guideline</i> https://www.cancercareontario.ca/en/gu	ng Module for Health Care Providers education s – Cervical Cancer. Retrieved from udelines-advice/cancer-
Cancer Care Manitoba's Cervical Cancer Screenin https://www.cancercare.mb.ca/screening/hcp/e Cancer Care Ontario (2020). <i>Screening Guideline</i> https://www.cancercareontario.ca/en/gu	ng Module for Health Care Providers I <mark>ducation</mark> s – Cervical Cancer. Retrieved from
Cancer Care Manitoba's Cervical Cancer Screenin https://www.cancercare.mb.ca/screening/hcp/e Cancer Care Ontario (2020). Screening Guidelines https://www.cancercareontario.ca/en/gu continuum/screening/resources-healthca summary	ng Module for Health Care Providers education s – <i>Cervical Cancer</i> . Retrieved from <u>uidelines-advice/cancer-</u> are-providers/cervical-screening-guidelines-
Cancer Care Manitoba's Cervical Cancer Screenin https://www.cancercare.mb.ca/screening/hcp/e Cancer Care Ontario (2020). Screening Guidelines https://www.cancercareontario.ca/en/gu continuum/screening/resources-healthca summary	ng Module for Health Care Providers a <u>ducation</u> s – <i>Cervical Cancer</i> . Retrieved from <u>udelines-advice/cancer-</u> are-providers/cervical-screening-guidelines- e (2016). Pelvic Exam: Summary of
https://www.cancercare.mb.ca/screening/hcp/e Cancer Care Ontario (2020). Screening Guidelines https://www.cancercareontario.ca/en/gu continuum/screening/resources-healthca summary Canadian Task Force of Preventative Health Care	ng Module for Health Care Providers <u>iducation</u> <u>s – Cervical Cancer</u> . Retrieved from <u>idelines-advice/cancer-</u> <u>are-providers/cervical-screening-guidelines-</u> <u>e (2016)</u> . Pelvic Exam: Summary of cy makers. Retrieved from
Cancer Care Manitoba's Cervical Cancer Screenin https://www.cancercare.mb.ca/screening/hcp/e Cancer Care Ontario (2020). Screening Guidelines https://www.cancercareontario.ca/en/gu continuum/screening/resources-healthca summary Canadian Task Force of Preventative Health Care recommendations for clinicians and poli https://canadiantaskforce.ca/guidelines, College of Nurses of Ontario. (2008). Practice Sta	ng Module for Health Care Providers iducation s – <i>Cervical Cancer</i> . Retrieved from <u>uidelines-advice/cancer-</u> are-providers/cervical-screening-guidelines- e (2016). Pelvic Exam: Summary of cy makers. Retrieved from <u>/published-guidelines/pelvic-exam/</u>
Cancer Care Manitoba's Cervical Cancer Screening https://www.cancercare.mb.ca/screening/hcp/e Cancer Care Ontario (2020). Screening Guidelines https://www.cancercareontario.ca/en/gu continuum/screening/resources-healthca summary Canadian Task Force of Preventative Health Care recommendations for clinicians and poli https://canadiantaskforce.ca/guidelines, College of Nurses of Ontario. (2008). Practice Sta https://www.cno.org/en/learn-about-sta	ng Module for Health Care Providers iducation s – Cervical Cancer. Retrieved from idelines-advice/cancer- are-providers/cervical-screening-guidelines- e (2016). Pelvic Exam: Summary of cy makers. Retrieved from /published-guidelines/pelvic-exam/ andard: Documentation. Retrieved from andards-guidelines/standards-and-guidelines/
Cancer Care Manitoba's Cervical Cancer Screening https://www.cancercare.mb.ca/screening/hcp/e Cancer Care Ontario (2020). Screening Guidelines https://www.cancercareontario.ca/en/gu continuum/screening/resources-healthca summary Canadian Task Force of Preventative Health Care recommendations for clinicians and poli https://canadiantaskforce.ca/guidelines, College of Nurses of Ontario. (2008). Practice Sta https://www.cno.org/en/learn-about-sta College of Nurses of Ontario. (2006). Practice Sta Retrieved from https://www.cno.org/en guidelines/	ng Module for Health Care Providers <u>ducation</u> s – <i>Cervical Cancer</i> . Retrieved from <u>idelines-advice/cancer-</u> <u>are-providers/cervical-screening-guidelines-</u> e (2016). Pelvic Exam: Summary of cy makers. Retrieved from <u>/published-guidelines/pelvic-exam/</u> <i>andard: Documentation.</i> Retrieved from <u>andards-guidelines/standards-and-guidelines/</u> andard: Therapeutic Nurse-Client Relationship. <u>/learn-about-standards-guidelines/standards-and-</u> uctkar-Flude, M. (2014). Physical Examination and

Mills, J. & Fitzgerald, M. (2008). Renegotiating roles as part of developing collaborative practice: Australian nurses in general practice and cervical screening. *Journal of Multidisciplinary Healthcare, 1,* 35-43.

Public Health Agency of Canada. (2013). *Canadian Guidelines on Sexually Transmitted Infections*. Retrieved from <u>http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php</u>

- Stewart, R., Thistlethwaite, J., & Buchanan, J. (2009). Can rural practice nurses, physician assistants and nurse practitioners fulfill patient expectations regarding "Well Woman Checks"? 10th National Rural Health Conference. Retrieved from <u>http://eprints.jcu.edu.au/5328/</u>
- Thistlethwaithe, J. (2010). Pap tests: What do women expect? *Australian Family Physician, 39*(10), 775-778.
- Tonelli, M. et al. (2016). Recommendations on routine screening pelvic examination: Canadian Task Force on Preventive Health Care adoption of the American College of Physicians guideline. *Canadian Family Physician, 62*(3). Retrieved from: <u>http://www.cfp.ca/content/62/3/211</u>
- White Hilton, L., Jennings-Dozier, K., Bradley, P., Lockwood-Rayermann, S., DeJesus, Y., Stephens, D. et al. (2003). The Role of Nursing in Cervical Cancer Prevention and Treatment. *Cancer*, 98(S9), 2070-2074.

NOTE:

This medical directive is based on TCFHT's previous medical directive RN-2PELVIC entitled, "Pelvic Examination," which required revision in formatting to reflect the growth of the TCFHT organization. The majority of the content of RN-2PELVIC has remained the same for the revised TCFHT-MD06 version. Therefore, all approved Implementers and Authorizers for medical directive RN-2PELVIC "Pelvic Examination," have grandfathered approval for TCFHT-MD06 "Pelvic Examination."

Appendix A:						
Authorizer Approval Form						
Name	Signature	Date				

TCFHT-MD06_Pelvic Examination	Appendix B:	
	Implementer Approval Form	1
To be signed when the imple	ementer has completed the required pre	eparation, and feel they have the
knowledge, skill, and judgem	nent to competently carry out the action	ns outlined in this directive.
Name	Signature	Date
	·	
	<u>-</u>	
	· · · · · · · _ · _ · _ · _ · _ · _ · · _ ·	
	·	

Appendix C

Sample Lab Requisition

Addi 790	e ienne Lemos ress Bay Street	of Health Ig-Term Care cry Requisition ioning Cinician			Lat	voratory Use Only						
	te 300				Clir	ician/Practifioner's Contact Numberfor Urg	ent Result	s		Service Da yyyy r	te mm	dd
Tor	onto, ON M5G 1N8				(416) 960-1366 Ext.						
Clini	ician/Practitioner Number	CP	SO/Registrati	on No.	Hea	ith Number	Version	Sex		Date of	Birth mm	dd
029	9015	93.	244			8575 897 163		XM	F	2000	01	01
Che	ck (🗸) one:				Prov	vince Other Provincial Registration Number			Patients	s Telephone Contact N	lumber	
XC	XHIP/Insured 🗌 Thi	rd Party / Unin	sured	WSB					()		
Add	itional Clinical Informatio	n (e.g. diagnos	is)		Pat Te	ient's Last Name <i>(as per OHI</i>P Card) st						
						ient's First & Middle Names <i>(as per OHIP C</i> tient	ard)					
X	Copy to: Clinician/Practiti	ioner				ent's Address (including Postal Code)						
	Name:	First Nar	ne		1	23 College st.						
DEF		Test				N						
Addr	ess											
Not	e: Separate requisitio	ns are requi	red for cytol	logy. his	lolo	gy / pathology and tests performed i	by Publ	ic Heal	h Labor	atory		
x	Biochemistry				x	Hematology	-			atitis (check one o	only)	
	Glucose	Random	Fastir	10		CBC			cute Hepa			
	HbA1C				Prothrombin Time (INR)				Chronic Hepatitis			
	Creatinine (eGFR)					Immunology				mune Status / Previous Exposure		
	Unic Acid				Pregnancy Test (Urine) Mononucleosis Screen Rubella Prenatat ABO, RhD, Antibody Screen			s	pecify.	Hepatitis A		
	Sodium							Hepetitis B Hepetitis C or order individual hepetitis Cther Tests' section below Prostate Specific Antigen (PSA)				
	Potassium											
	ALT											
	Alk. Phosphatase											
	Bilirubin				Repeat Prenatal Antibodies			Total PSA Free PSA				
	Albumin				Microbiology ID & Sensitivities			Specify one below:				
	Lipid Assessment (includ	ies Cholesterol	HDL-C Trink	reides		(if warranted)		Insured – Meets OHIP eligibility criteria				
	calculated LDL-C & Cho	MHDL-C ratio; ir	dividual lipid te	ests may		Cervical		🗌 Unin	sured – Sc	reening: Patient respor	nsible for	payment
	be ordered in the "Other	lesis secuditi	a unis iormj		X Vaginal			Vitamin D (25-Hydroxy)				
	Alburnin / Creatinine Rat	iio, Unine			Vaginal / Rectal – Group B Strep			🗌 insu		Is OHIP eligibility crite		
	Uninalysis (Chernical)				Chlamydia (specify source): cervix			osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes;				romes;
\vdash	Neonatal Bilirubin:			-	X	GC (specify source): cervix				ications affecting vitan dient responsible for pa		tabolism
\vdash	Child's Age:	days	1	hours		Sputum					ауптан	
\vdash	Clinician/Practitioner's to Dational's 24 to to both				-	Throat		Othe	r lests -	one test per line		
\vdash	Patient's 24 hr telephone Therapeutic Drug Monito				-	Wound (specify source): Unine						
\vdash	Name of Drug#1				-	Stool Culture						
╽┝	Name of Drug#2				-	Stool Cva & Parasites						
	Time Collected #1	hr.	#2	hr.		Other Swabs / Pus (specify source):						
†	Time of Last Dose #1	hr.	#2	hr.								
	Time of Next Dose #1	hr.	#2	hr.	Spe	cimen Collection						
Ih	ereby certify the tests or			în or	Tim	e #2100pmck Date 2024/04	/24					
	t patients of a hospital.		-		Fee	cal Occult Blood Test (FOBT) (check	(one)					
					FOBT (non CCC)	cerCheck	FOBT (CCC) no o	ther test can be order	ed on thi	is form	
				Lat	oratory Use Only							
	ki McGregor RN											
As	per medical direc	tive TCFH	F-MD 06									
	MALANA											
x	<u>X_N</u>		24/04/2024									
	ician/Practitioner Signatur		Date									
4422-4	84 (2013/01) 🛛 🛛 Queen's Pri	inter for Ontario, 2	013									7530-4581

9

General Test Requisition

ALL sections of the form must be completed by <u>authorized</u> health care providers for each specimen submitted, or testing may be delayed or cancelled. Verify that all testing requirements are met before collecting a specimen. For HIV, respiratory viruses, or culture isolate requests, use the dedicated

Ordering Healthcare F	havidan Information	Patient Infe	ormation	
Ordering Healthcare F	care Provider Full Name:	Health Card No	ON 8575 897 163	
029015	Vivienne Lemos	Date of Birth (v	/yy-mm-dd): 2000-01-01	Sex: Male
Org. Name: Taddle Creek F	HT Address: Bay Street Suite 30			Female
City: Toronto	Postal Code: M5G 1N8 Province: ON	Last Name (per health card):	Test	
Tel: 416-960-1366		First Name (per health card):	Patient	
	Other Authorized Healthcare Provider	Address: 123	College st	Postal
	lealth Unit / Other Authorized Provider Name:	City:		Code: Tel:@gmail.con
			Outbreak No. from	
Org. Name:	Address:		Unit (if applicable):	
City:	Postal Province:	Encol - Encoloring to the	Information	
Tel:	Fax:	Date Coll (yyyy-mm)		ubmitter ab No.:
		Whole Blo	ood Serum	Plasma
Patient Setting		Bone Mar	row Cerebrospina Fluid (CSF)	Nasopharynge Swab (NPS)
	R (Not Admitted / lot Yet Determined) ER (Admitte	Orophary	ngeal Southum	Bronchoalveol
(Non-ICU)	CU / CCU Congregate	9 Endocervi	wab ·	Lavage (BAL)
Testing Indication(s) /	Criteria	Swab		
Diagnosis X S	creening Immune Follow-up / Status Convalesce	Urine	Rectal Swab	Faeces
	npaired Post- nmunity mortem	Other (Specify t AND body locat		
Other (Specify):		Test(s) Red	quested	
Signs / Symptoms			ay as per the <u>publichealthon</u>	tario.ca/testdirectory:
	nset Date			
	yyy-mm-dd): Fever Rash STI	^{2.} Chlamyd 3.	ia NAA I	
Gastrointestinal Gastrointestinal	Respiratory Hepatitis Encepha	itis 1.		
Specify):		5.		
Relevant Exposure(s)		6.		
	Recent Date	For routine hep	atitis A, B or C serology, con	
Occupational		Hepatitis A ed	(HAV IgG)	Acute Infection (HAV IgM, signs/ symptoms info)
Other Specify): Sexually active	e, male partners	Hepatitis B	Immune Status (anti-HBs)	Chronic Infection (HBsAg + total anti-HB
Relevant Travel(s)		[Acute Infection (HBsAg + total anti-HBc	Pre-Chemotherapy Screening (anti-HBs
	Recent Date		+ IgM if total is positive)	HBsAg + total anti-HBc
Travel	-mm-dd):	Hepatitis C	Current / Past Infection No immune status test for	
Details:	collected under the authority of the Personal Health I			

purpose of clinical laboratory testing. If you have questions about the collection of this personal health information please contact the PHO's Laboratory Customer Service at 416-235-6556 or toll free 1-877-604-4567. F-SD-SCG-1000, version 004 (September 2023).

Public Health Ontario

PHO Lab No .:

For Public Health Ontario's laboratory use only:

Date Received (yyyy-mm-dd):

Santé publique Ontario

Appendix D

Sample Cytology Requisition

Dynacare [.]	Laboratory U	ise Only			Cytology R	eference Number		
Requisitioning Clinics /Practitioner Name Vivienne Lemos								
Address 790 Bay Street								
Suite 300 Toronto, ON M5G 1N	10		Ciinician / Prac	titioner's Contact i	Number	for Urge	nt Results	Service Date
· · · · · · · · · · · · · · · · · · ·			416-96 0 -1	-		Ext		2024/04/24
Clinicus/Practitioner Mumber 029015	CPSO/Registration N	umber	Health Card Nu ON 8575 8			Version	Sax	Date of Birth
Check (/) one:	L			winclel Registration Num			М	2000/01/01
OHIP/Insured Third P	arty/Uninsured	🗍 WSIB		and the second second second second				Health Card Expiry
Copy to: Cliniclen / Practilianer CP	50 4			(as per Hasiin Care)	•			<u></u>
Name			Test					<u> </u>
			Patient's First Name Patient	(as per Hostih Card)			Patier	t's Middle Name (as per Nostih Cand)
Address				cluding Postal Code)				<u> </u>
			123 Colle	ge st.ON				
Name				-				
Address			Postzi Code					
Patient's Chart Humber 1	Specimen Collection To	me .	Specimen Co	ection Date	Patient's T	elephone Ca	sniact Number	
35697	5:19PM		2024/04/2	24		()	Ext.
CVNEC						CVNE.		CYTOLOGY
GINEC		OLOGI			non	GINE		
Pap Test according to O				10 # 01	Specin	iens Sub	mitted	# Of Slides Submitted
Date of LMP (First Day) Marc	h 24, 2024			Urine:	Voide	d	Cathete	rized
Site: Cervical	Combined	Endocervica	I Vaginal					Nodule Single Mult
	Liquid Base	Conventi		Body Fluids:			Peritone	
Collection Instrument:	Brush	Broom	Spatula	Synovial Fluid	± [Left	Right	
Cervix [Normal	Suspictor	1\$	Breast: Le		Right		Nodule (Nipple Discharge
	INCY (#wits)	Post Part	um (øwka)					
	enopausal enopausal Blee	dina		Other Site: (S	pecity;	· <u> </u>		
				Clinical Histor	y/Ren	arks:		
			ix Present					
	nt Vaccinated fi							
Previous Abnormal Cyto		—						
	Result/Da	ite:						
STI Testing on ThinPrep: in	addition MOH re	quisition is requ	ilred.	Laboratory	Use	Öniy]	Fixative Added Yes No
Chlamydia NAAT Gor	iorrhea NAAT	Trichon	ionas NAAT	Description:			L	
HPV: Patient will be billed for	HPV lest.			-	wy 🛄 I	Sloody [Watery 📋 🤇	liear 🔲 Turbid 🔲 Flocculent
HPV test only HPV	/ & Pap test	HPV tes	it (If ASCUS)	Color				/clume mi
Clinical information is impo I hereby certify the test order	rei			ests. Please prov Medical Dire				ormation. 24, 2024
Claiden/Precificener S 80100 99/2017 (REQU-CYTO-05)	lgnaturo						_	

11